Estimated event date.Estimated implant.The device was not returned for analysis.A review of the lot history record and complaint history of the reported lot could not be conducted because the lot and part number were not provided.A conclusive cause for the difficulties listed can not be determined based on the limited information available.The patient effects listed are consistent with the product risk profile and are therefore expected.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.Literature attachment.Article title: very late scaffold thrombosis after everolimus-eluting bioresorbable scaffold implantation in patients with unremarkable interim surveillance angiography.The udi number is unknown as the part and lot #s were not provided.
|
Patient 4.It was reported that this patient was featured in a journal article titled, "very late scaffold (vlsct) thrombosis after everolimus-eluting bioresorbable scaffold (brs) implantation in patients with unremarkable interim surveillance angiography".The patient underwent right coronary artery (rca) intervention with implantation of a 3.5/12 mm bioresorbable scaffold (brs).Follow-up angiography showed good results without significant restenosis.478 days after the index procedure, the patient presented with stemi (st elevation myocardial infarction).Coronary angiography showed vlsct with thrombotic occlusion of the brs in the proximal rca.After thrombus aspiration and balloon dilatation, a des (drug eluting stent) was implanted.No additional information was provided.
|